Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms Duobody(R)-CD3xB7H4 + [1] |
Target |
Mechanism B7-H4 modulators(V-set domain-containing T-cell activation inhibitor 1 modulators), CD3 modulators(T cell surface glycoprotein CD3 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 2 | GB | 13 Dec 2021 | |
Breast Cancer | Phase 2 | NL | 13 Dec 2021 | |
Breast Cancer | Phase 2 | ES | 13 Dec 2021 | |
Breast Cancer | Phase 2 | DK | 13 Dec 2021 | |
Breast Cancer | Phase 2 | FR | 13 Dec 2021 | |
Breast Cancer | Phase 2 | PL | 13 Dec 2021 | |
Breast Cancer | Phase 2 | US | 13 Dec 2021 | |
Breast Cancer | Phase 2 | BE | 13 Dec 2021 | |
Breast Cancer | Phase 2 | IT | 13 Dec 2021 | |
Ovarian Cancer | Phase 2 | BE | 13 Dec 2021 |